About Syntara

Pharmaxis Ltd., a specialty pharmaceutical company, focuses on the development of products for the diagnosis and treatment of chronic respiratory and immune disorders primarily in Australia. Products Bronchitol The company is developing Bronchitol, its proprietary, inhaled dry powder mannitol formulation, for the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and bronchiectasis; and for the treatment of other acute and chronic pulmonary conditions. Bronchitol for Cystic fibrosis: The company has completed Phase III clinical trial of Bronchitol in patients with CF in Europe and Australia. Bronchitol for Bronchiectasis: The company has completed Phase III clinical trial of Bronchitol for bronchiectasis in Europe and Australia. It is seeking marketing approval. Bronchitol for other pulmonary indications: Bronchitol has potential application to other pulmonary conditions, such as COPD and patients within hospital intensive care units. Aridol The company has developed Aridol (mannitol bronchial challenge test), as a tool for the detection of airway hyperresponsiveness and to assist in the diagnosis and management of asthma. The Aridol test mimics the bronchoconstriction that can occur in inflamed airways in people with asthma. Aridol may also be used to determine the minimum effective doses of inhaled corticosteroid required for optimum control of asthma. It supplies Aridol in Australia. It has also received marketing approval to Aridol in Germany, France, the United Kingdom, Italy, the Netherlands, Belgium, Denmark, Greece, Finland, Ireland, Norway, Sweden, Portugal, and South Korea. Preclinical Pipeline The company’s preclinical pipeline is focused on treatments for fibrotic and inflammatory diseases, including asthma and other pulmonary conditions. PXS25 has been identified as an antifibrotic agent and PXS4159 has been identified as an anti-inflammatory agent. PXS25 is in development for the treatment of pulmonary fibrosis (IPF). Preclinical trials have been completed with PXS25 and intend to commence Phase I clinical trials. Preclinical trials are in progress with PXS4159 to determine its suitability for Phase I human clinical trials. PXS25 is an inhibitor of the mannose 6 phosphate receptor and PXS4159 is an inhibitor of semicarbazide sensitive amine oxidase/vascular adhesion protein-1. Competition The company identifies competition from AstraZeneca; Methapharm, Inc.; Gilead Sciences, Inc.; Novartis AG; AOP Orphan; Pharmaceuticals AG; and Inspire Pharmaceuticals, Inc. History The company was incorporated in 1998 under the name Praxis Pharmaceuticals Australia Pty Ltd. in 1998 and changed its name to Pharmaxis Pty Ltd. in 2002. Further, it changed its name to Pharmaxis Ltd. in 2003.